Table 1.

Description and origin of HNSCC cell lines including therapy received and survival of patients whose tumors were established in culture.

UM-SCC 10A	Larynx carcinoma (T3), biopsy taken during surgical treatment, survival time 22 months
UM-SCC 10B	Biopsy of metastasis in a cervical lymph node of the primary tumor UM-SCC 10A
UM-SCC 11B	Larynx carcinoma (T2N2a) after chemo- therapy with CIS and BLM. Biopsy taken during surgery, survival time 14 months
UM-SCC 14A	Recurrent carcinoma of the mouth (T1N0) after repeated surgical treatment and radio- therapy. Biopsy taken during surgery, survival time 93 months
UM-SCC 14B	Biopsy of second recurrence of carcinoma UM-SCC 14A before treatment
UM-SCC 14C	Biopsy of third recurrence of carcinoma UM-SCC 14A after surgery and chemoradiotherapy with 5-FU, VCR and MTX
UM-SCC 22B	Metastasis in a cervical lymph node of a previously untreated hypopharynx carcinoma (T2N1M0), survival time 10 months
HLac 79	Metastasis in a cervical lymph node of a larynx carcinoma
8029 NA	Recloned subpopulation of HLac 79 (limiting dilution)
8029 DDP	variant of 8029 NA with experimentally induced CIS resistance